Glipizide tablets are indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM;type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory.In initiating treatment for non-insulin-dependent diabetes, diet should be emphasized as the primary form of treatment.
Caloric restriction and weight loss are essential in the obese diabetic patient.
Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia.
The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified, and corrective measures taken where possible.
If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered.
Use of Glipizide tablets must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint.
Furthermore, loss of blood glucose control on diet alone also may be transient, thus requiring only short-term administration of Glipizide tablets. During maintenance programs, Glipizide tablets should be discontinued if satisfactory lowering of blood glucose is no longer achieved.Judgments should be based on regular clinical and laboratory evaluations.In considering the use of Glipizide tablets in asymptomatic patients, it should be recognized that controlling the blood glucose in non-insulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes.
Glipizide tablets are contraindicated in patients with:Known hypersensitivity to the drug.Diabetic ketoacidosis, with or without coma.This condition should be treated with insulin.